Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis

The duration of the study period for a participant was approximatively 44 weeks broken down as follows: * Screening period up to 4 weeks, * 24-week double-blind treatment period\*, * 16-week post-treatment elimination follow-up period. '\*' Participants successfully completing the week 24 visit were offered the opportunity to enter the optional long-term extension study LTS6047 - NCT00811395.